Literature DB >> 9572540

Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis.

I Taskintuna1, F M Rahhal, E V Capparelli, K C Cundy, W R Freeman.   

Abstract

This study was undertaken to evaluate the intravitreal and plasma concentrations of cidofovir (HPMPC) after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis. Cohort series; undiluted vitreous and blood were collected from 9 patients at the time of pars plana vitrectomy. Vitreous samples from 9 eyes of 9 patients and plasma samples from 4 patients were assayed with high-performance liquid chromatography to determine cidofovir levels. The only eye that had a detectable vitreous concentration (673.7 ng/ml) was injected with 20 microg 24 hours prior to the surgery. The remaining samples including plasma were below the detection point of the assay (100 ng/ml) and were injected between 5 and 40 days prior to sampling. The intravitreal concentration of cidofovir in humans is consistent with pharmacokinetics data in laboratory animals, and suggests that the long duration of antiviral effect (1-3 months) in clinical trials is due to a prolonged intracellular half-life in retinal tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9572540     DOI: 10.1089/jop.1998.14.147

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  2 in total

1.  Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.

Authors:  Feiyan Ma; Kaihui Nan; SuNa Lee; James R Beadle; Huiyuan Hou; William R Freeman; Karl Y Hostetler; Lingyun Cheng
Journal:  Eur J Pharm Biopharm       Date:  2014-12-13       Impact factor: 5.571

2.  Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6.

Authors:  Hyoung J Koh; Kenichiro Bessho; Lingyun Cheng; Dirk-Uwe Bartsch; Terence R Jones; Germain Bergeron-Lynn; William R Freeman
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.